CC-4066 in organ preservation

Organ transplantation involves the distinct phases of organ procurement (including storage and transportation) and implantation surgery. The main determinant of the long-term patient survival is the quality of the transplanted organ, which depends to some extent on the quality of the organ. However, the main enemy is time, the length of the period between removal of the organ from the donor to the moment of post-transplantation resuscitation of the recipient being a strong predictor of successful transplantation. During this period of storage and transport the organ is exposed to significant stress due to hypoxia and nutrient deprivation, leading to progressive deterioration of the functional capability of the organ and triggering the onset of inflammation.

Cypralis’ drug candidate is a water-soluble small molecule scheduled to enter first in human trials in Q1 2021. In animal experiments of organ protection use of the drug in conjunction with current preservation protocols has been shown by histopathology and immunohistochemistry to result in significantly reduced tissue damage and inflammation. This drug has the potential to significantly prolong organ storage times and improve the quality of transplanted organs with the overall benefit of reduced organ supply pressure, better long-term outcomes and significant cost savings. Clinical studies will begin early in 2021 with the goal to define the best positioning of this drug in organ preservation and transplantation.

Please contact us to explore opportunities for collaboration or investment.